Turn Therapeutics reports Stage 1 atopic dermatitis data, speeds up HS trial

Turn Therapeutics reported corporate updates and third-quarter 2026 financial results on November 9, 2026. In October 2026, the company had disclosed additional findings from the complete 50-patient Stage 1 trial population studying GX-03 in atopic dermatitis. At four weeks, 59.3% of GX-03 patients reached clear or almost clear skin versus 30.4% on vehicle, a gap of 28.8 percentage points.¹ By week 8, 40.7% of GX-03 patients hit EASI-100, meaning no visible eczema remained, compared with 17.4% on vehicle.¹ Among the subset with severe itch at baseline, 61.5% treated with GX-03 achieved clear or almost clear skin at four weeks versus 8.3% on vehicle.¹

The ongoing Phase 2b trial is testing GX-03 in 120 to 136 atopic dermatitis patients with severe itch and a range of skin involvement, comparing it against an ointment vehicle on skin clearance and EASI-based severity measures.¹ The company said the Phase 2b trial has had no dropouts so far, while the completed Phase 2a trial had a dropout rate below 5% with no treatment-related discontinuations.¹ Turn expects topline Phase 2b results in the first quarter of 2027.¹

Separately, the company is accelerating enrollment in its planned Phase 2a hidradenitis suppurativa trial, now expected to begin in the first quarter of 2027 instead of the previously targeted second quarter.¹ That roughly 80-patient trial will compare GX-03 to a matched ointment placebo on active inflammatory lesions and pain.¹

On September 9, 2026, Turn Therapeutics named former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer.¹

The company held $10.4 million in cash and cash equivalents as of September 30, 2026.¹ It said this is expected to fund the ongoing Phase 2b atopic dermatitis trial and the planned Phase 2a HS trial, with operations funded into the third quarter of 2027.¹